Chemours: 'Given weaker demand outlook, we now anticipate full year Adjusted EBITDA to be between $1.025 billion and $1.075 billion; with Adjusted Free Cash Flow guidance greater than $225 million'
Portfolio Pulse from Benzinga Newsdesk
Chemours has revised its full-year Adjusted EBITDA forecast to between $1.025 billion and $1.075 billion due to a weaker demand outlook. The company also expects its Adjusted Free Cash Flow guidance to be greater than $225 million.
October 26, 2023 | 8:43 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Chemours has lowered its full-year Adjusted EBITDA forecast due to weaker demand, which could negatively impact its stock price in the short term.
Chemours' revised EBITDA forecast indicates a weaker demand outlook, which could lead to lower revenues and profits. This could negatively impact investor sentiment and put downward pressure on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100